ATM Kinase Inhibition and Metabolic Modulation in High Grade Serous Ovarian Cancer: Synergy with Fenofibrate

Study Background and Research Question

High grade serous ovarian cancer (HGSOC) remains the deadliest gynecological malignancy, with most patients diagnosed at advanced stages and facing a five-year survival rate below 30% (source: paper). While current therapies—including surgery, platinum-based chemotherapy, and PARP inhibitors—have transformed outcomes for patients with homologous recombination (HR) deficiency, approximately half of HGSOC cases are HR-proficient and do not benefit from these strategies. This situation creates an urgent need for new treatment modalities for HR-proficient HGSOC. Given the central role of the Ataxia Telangiectasia Mutated (ATM) kinase in HR-mediated DNA double-strand break (DSB) repair, the study asks whether targeting ATM kinase in HR-proficient tumors could sensitize these otherwise resistant tumors to alternative treatments, particularly those affecting cellular metabolism.

Key Innovation from the Reference Study

The study provides a novel mechanistic insight: ATM expression and activity are upregulated in HGSOC compared to normal fallopian tube tissue, and this upregulation is inversely associated with metabolic pathway activity (source: paper). Through bioinformatic analyses and experimental validation, the authors identify that combining ATM inhibition with fenofibrate—a clinically approved PPARα agonist—synergistically induces senescence in multiple HGSOC cell lines. This combination leverages the metabolic vulnerabilities created by ATM inhibition, representing a new therapeutic angle for HR-proficient ovarian cancers.

Methods and Experimental Design Insights

The research team employed a combination of transcriptomic analysis, drug sensitivity screening, and in vitro cell-based assays:

• Analysis of HGSOC patient samples and cell lines revealed that ATM is wild-type and highly expressed, with its expression correlating inversely with metabolic gene signatures.
• Drug sensitivity data from the Dependency Map (DepMap) resource indicated that cells with low ATM expression are more sensitive to fenofibrate, supporting the hypothesis of a synthetic lethal interaction.
• Cellular assays tested the effects of ATM inhibition, fenofibrate, and their combination on cell proliferation, senescence induction, and metabolic gene expression in several HGSOC cell lines.

The design integrates both large-scale computational analyses and rigorous laboratory validation to build a mechanistic framework for combination therapy.

Core Findings and Why They Matter

1. ATM as a Therapeutic Target in HR-Proficient HGSOC
ATM activity is increased in HGSOC relative to normal tissue, and high nuclear ATM expression correlates with worse patient survival. In the HR-proficient context, where standard therapies are ineffective, ATM inhibition emerges as a rational strategy (source: paper).

2. Metabolic Pathways Are Inversely Correlated with ATM
Gene set enrichment and correlation studies reveal that samples with high ATM expression display reduced activity in metabolic pathways, particularly those regulated by PPARα. This observation suggests that metabolic reprogramming accompanies ATM activation in HGSOC.

3. Fenofibrate Sensitivity and Synergy with ATM Inhibition
Cells with low ATM are more sensitive to fenofibrate, and PPARα signaling is functionally linked to ATM status. Experimental data show that the combination of ATM inhibition and fenofibrate induces robust senescence in HGSOC cell models, exceeding the effects of either agent alone. This synergy is mechanistically attributed to metabolic stress and impaired DNA repair capacity (source: paper).

4. Implications for Treatment-Resistant Ovarian Cancer
The results suggest a new therapeutic paradigm for HR-proficient HGSOC, targeting both DNA damage response (DDR) via ATM inhibition and metabolic adaptation via PPARα agonism. Notably, this approach exploits vulnerabilities not addressed by existing standard-of-care regimens.

Comparison with Existing Internal Articles

A series of internal resources focus on the role of ATM kinase inhibition in glioma research, particularly using KU-60019 as a tool compound (internal article 1, internal article 2). These articles detail how KU-60019, a potent and selective ATM kinase inhibitor, enables radiosensitization and inhibits cell migration and invasion in glioma models. While the tumor type differs, the mechanistic rationale overlaps: both glioma and HGSOC studies demonstrate that ATM inhibition disrupts the DNA damage response and impairs cancer cell survival mechanisms. Notably, the internal articles emphasize the selectivity profile and experimental versatility of KU-60019, supporting its use in dissecting ATM-dependent signaling and metabolic adaptation. The current ovarian cancer study extends these concepts to a new context, showing that ATM inhibition can be leveraged not only for radiosensitization but also to sensitize cancer cells to metabolic therapies, broadening the scope of ATM-targeted research.

Protocol Parameters

• cell viability assay | 3 μM (KU-60019) | in vitro HGSOC, glioma | Standard concentration for ATM kinase inhibition in cell-based assays; enables assessment of proliferation, radiosensitization, and metabolic modulation | product_spec
• intratumoral delivery | 10 μM (KU-60019) | in vivo xenograft models | Dose used for continuous local delivery via osmotic pump to achieve effective ATM inhibition in tumor tissue | product_spec
• fenofibrate co-treatment | 10–50 μM | in vitro HGSOC | Doses used to evaluate synergistic effects with ATM inhibition on senescence induction | paper
• storage recommendation | -20°C (KU-60019 stock) | all applications | Ensures compound stability and reproducibility of results | product_spec
• solubility | ≥27.4 mg/mL in DMSO (KU-60019) | in vitro prep | High solubility supports stock solution preparation for cell-based experiments | product_spec

Limitations and Transferability

While the study robustly demonstrates synergy between ATM inhibition and fenofibrate in vitro, several limitations warrant consideration:

• All synergy data are derived from cell line models; clinical translational potential remains to be established in animal models or human studies.
• The underlying mechanisms connecting ATM signaling, metabolic reprogramming, and senescence require further elucidation, particularly in the context of tumor heterogeneity.
• Potential off-target effects of both ATM inhibitors and fenofibrate at higher concentrations must be accounted for in protocol optimization.

Transferability to other cancer types is supported by mechanistic overlap with glioma models, as discussed in internal resources, but rigorous validation is needed for each context (source: internal article 1).

Research Support Resources

Researchers aiming to dissect ATM kinase signaling pathways or explore combination strategies in ovarian cancer or other solid tumors can utilize KU-60019 (SKU A8336), a highly selective ATM kinase inhibitor with robust performance in both cell-based and in vivo workflows (source: product_spec). Detailed protocols, solubility guidance, and application notes are available from APExBIO to facilitate reproducible experimental design. For cell experiments, stock solutions in DMSO can be stored at -20°C and used at concentrations typically ranging from 3 μM in vitro to 10 μM in vivo, as also recommended in prior glioma and ovarian cancer research (source: product_spec, paper).